The disease, caused by a bacteria producing toxic substances which lead to internal bleeding, swelling and tissue death, is listed as the main biological terror threat to Brits.
Y Combinator has broadened its investment focus beyond the seed funding it gives to startups in its accelerator batches, and has become one of the most active investors in the country in subsequent stages.
GlaxoSmithKline divested its portfolio of rare disease gene therapies to Orchard Therapeutics through a strategic agreement, the company announced April 12.
The Johns Hopkins University and Lockheed Martin today announced a partnership aimed at enhancing opportunities for Baltimore City public school students pursuing academic and career fields in science, technology, engineering, and math. The collaboration is designed to close the STEM gap that exists primarily in Pre-K through 12th grade.
Emergent BioSolutions Inc. (NYSE:EBS) today announced the successful completion of the Mutual Recognition Procedure (MRP) for market authorization of BioThrax® (Anthrax Vaccine Adsorbed) in five Concerned Member States (CMS) within the European Union (EU), including Italy, the Netherlands, Poland, the U.K., and France (where it will be marketed as BaciThrax™). Emergent filed the mutual recognition application based on the existing Marketing Authorization of BioThrax in Germany granted by the Paul-Ehrlich-Institut. Following the positive MRP outcome, national licenses are due to be issued shortly by the five CMS countries.
This year marks the 70th Anniversary of the National Heart, Lung, and Blood Institute (NHLBI). NHLBI began as the National Heart Institute on June 16, 1948, when President Harry S. Truman signed the National Heart Act. In 1969, the Institute expanded its mission (and name) to cover research on lung diseases, and in 1976, the Institute grew further to include blood disorders.
To commemorate the Institute’s 70th anniversary and showcase important investments in scientific research, NHLBI is featuring lectures throughout the year from prominent thought leaders representing areas of high scientific priority in heart, lung, blood, and sleep disorders.
D.C.-area tech companies who pulled in sizable investments contributed to a big venture capital fundraising quarter for the D.C. area to start 2018.
Enterprise Therapeutics Ltd, a biopharmaceutical company dedicated to the research and development of novel therapies for the treatment of respiratory diseases, today announced that it has closed an oversubscribed £29 million ($41 million USD) Series B round co-led by Versant Ventures and Novartis Venture Fund. The syndicate also included new investor Forbion, founding investor Epidarex Capital and existing investor IP Group.
Alexandria Real Estate Equities, Inc. (NYSE: ARE), an urban office REIT uniquely focused on collaborative life science and technology campuses in AAA innovation cluster locations, today announced the expansion of Alexandria LaunchLabs®—its premier, full-service life science startup platform—into the thriving East Cambridge life science ecosystem. Alexandria LaunchLabs will open in the fall of 2018 in One Kendall Square, one of the most sought-after locations for life science companies in the United States. Building upon the success of Alexandria LaunchLabs’ initial flagship site, which opened at the Alexandria Center® for Life Science – New York City in June 2017, the company will now bring its validated Alexandria LaunchLabs platform to Cambridge to meet the cluster’s critical demand for life science startup space.
The first annual Kendall Square Challenge, an app-driven fundraiser competition benefiting various nonprofits, will take place May 17 in Cambridge.